The clinical impact of thiopurine methyltransferase polymorphisms on thiopurine treatment

Nucleosides, Nucleotides and Nucleic Acids

Volumn 23, Issue 8-9, 2004, Pages 1385-1391

  Coulthard, S A ^a   Matheson, E C ^a   Hall, A G ^a   Hogarth, L A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

6 mercaptopurine; 6 thioguanine; Azathioprine; Leukaemia; Thiopurine methyltransferase (TPMT)

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AZATHIOPRINE; MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC ACTIVITY; CONFERENCE PAPER; DRUG EFFICACY; DRUG METABOLISM; ENZYME POLYMORPHISM; HUMAN; NUCLEIC ACID BASE SUBSTITUTION; PURINE METABOLISM; VARIABLE NUMBER OF TANDEM REPEAT;

6-MERCAPTOPURINE; ALANINE; ANTIMETABOLITES, ANTINEOPLASTIC; AZATHIOPRINE; DNA; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, LYMPHOCYTIC, ACUTE; METHYLTRANSFERASES; MODELS, BIOLOGICAL; MUTATION; PHENOTYPE; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; THIOGUANINE; TIME FACTORS; TYROSINE;

STAPHYLOCOCCUS PHAGE 3A;

EID: 10344223510     PISSN: 15257770     EISSN: None     Source Type: Journal    
DOI: 10.1081/NCN-200027637     Document Type: Conference Paper

References (34)

1. Bertino, J.R. Improving the curability of acute leukemia: pharmacologie approaches. Semin. Hematol. 1991, 28, 9-11.
2. Weinshilboum, R.M.; Sladek, S.L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. 1980, 32, 651-662.
3. Coulthard, S.A.; Rabello, C.; Robson, J.; Howell, C.; Minto, L.; Middleton, P.O.; Gandhi, M.K.; Jackson, G.; McLelland, J.; O'Brien, H.; Smith, S.; Reid, M.M.; Pearson, A.D.J.; Hall, A.G. A comparison of molecular and enzyme-based assays for the detection of thiopurine methyltransferase mutations. Br. J. Haematol. 2000, 110, 599-604.
4. Szumlanski, C.; Otterness, D.; Her, C.; Lee, D.; Brandriff, B.; Kelsell, D.; Spurr, N.; Lennard, L.; Wieben, E.; Weinshilboum, R. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol. 1996, 15, 17-30.
5. Coulthard, S.A.; Howell, C.; Robson, J.; Hall, A.G. The relationship between thiopurine methyltransferase activity and genotype in blasts from patients with acute leukemia. Blood 1998, 92, 2856-2862.
6. Coulthard, S.A.; Hall, A.G. Recent advances in the pharmacogenomics of thiopurine methyltransferase. Pharmacogenomics J. 2001, 1, 254-261.
7. Weinshilboum, R.M.; Raymond, F.A.; Pazmino, P.A. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin. Chim. Acta 1978, 85, 323-333.
8. McLeod, H.L.; Relling, M.V.; Liu, Q.; Pui, C.-H.; Evans, W.E. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 1995, 85, 1897-1902.
9. Kroplin, T.; Weyer, N.; Gutsche, S.; Iven, H. Thiopurine S-methyltransferase activity in human erythrocytes: a new HPLC method using 6-thioguanine as substrate. Eur. J. Clin. Pharmacol. 1998, 54, 265-271.
10. Yates, C.R.; Krynetski, E.Y.; Loennechen, T.; Fessing, M.Y.; Tai, H.L.; Pui, C.H.; Relling, M.V.; Evans, W.E. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann. Intern. Med. 1997, 126, 608-614.
11. Hall, A.G.; Hamilton, P.; Minto, L.; Coulthard, S.A. The use of denaturing high-pressure liquid chromatography for the detection of mutations in thiopurine methyltransferase. J. Biochem. Biophys. Methods 2001, 47, 65-71.
12. Schaeffeler, E.; Lang, T.; Zanger, U.M.; Eichelbaum, M.; Schwab, M. High-throughput genotyping of thiopurine S-methyltransferase by denaturing HPLC. Clin. Chem. 2001, 47, 548-555.
13. Coulthard, S.A.; Hogarth, L.A.; Little, M.; Matheson, B.C.; Redfern, C.P.; Minto, L.; Hall, A.G. The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. Mol. Pharmacol. 2002, 62, 102-109.
14. Yi, P.; Melnyk, S.; Pogribna, M.; Pogribny, I.P.; Hines, R.J.; James, S.J. Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation. J. Biol. Chem. 2000, 275, 29318-29323.
15. Lennard, L.; Van Loon, J.A.; Lilleyman, J.S.; Weinshilboum, R.M. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6- thioguanine nucleotide concentrations. Clin. Pharmacol. Ther. 1987, 41, 18-25.
16. Lennard, L.; Lilleyman, J.S.; Van Loon, J.; Weinshilboum, R.M. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990, 336, 225-229.
17. Schmiegelow, K.; Schroder, H.; Gustafsson, G.; Kristinsson, J.; Glomstein, A.; Salmi, T.; Wranne, L. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic society for pediatric hematology and oncology. J. Clin. Oncol. 1995, 13, 345-351.
18. Schutz, E.; Gummert, J.; Mohr, F.W.; Armstrong, V.W.; Oellerich, M. Azathioprine myelotoxicity related to elevated 6-thioguanine nucleotides in heart transplantation. Transplant. Proc. 1995, 27, 1298-1300.
19. Bostrom, B.; Erdmann, G. Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. Am. J. Pediatr. Hematol.-Oncol. 1993, 15, 80-86.
20. Lilleyman, J.S.; Lennard, L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 1994, 343, 1188-1190.
21. Leipold, G.; Schutz, E.; Haas, J.P.; Oellerich, M. Azathioprine-induced severe pancytopenia due to a homozygous two- point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B27-associated spondylarthritis. Arthritis Rheum. 1997, 40, 1896-1898.
22. Ben Ari, Z.; Mehta, A.; Lennard, L.; Burroughs, A.K. Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis. J. Hepatol. 1995, 23, 351-354.
23. Lennard, L.; Van Loon, J.A.; Weinshilboum, R.M. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin. Pharmacol. Ther. 1989, 46, 149-154.
24. Jackson, A.P.; Hall, A.G.; McLelland, J. Thiopurine methyltransferase levels should be measured before commencing patients on azathioprine. Br. J. Dermatol. 1997, 136, 133-134.
25. Evans, W.E.; Horner, M.; Chu, Y.Q.; Kalwinsky, D.; Roberts, W.M. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J. Pediatr. 1991, 119, 985-989.
26. Andersen, J.B.; Szumlanski, C.; Weinshilboum, R.M.; Schmiegelow, K. Pharmacokinetics, dose adjustments, and 6- mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency. Acta Paediatr. 1998, 87, 108-111.
27. Lennard, L.; Gibson, B.E.S.; Nicole, T.; Lilleyman, J.S. Congenital thiopurine methyltransferase deficiency and 6- mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch. Dis. Child. 1993, 69, 577-579.
28. Krynetski, E.Y.; Evans, W.E. Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm. Pharm. Res. 1999, 16, 342-349.
29. Evans, W.E.; Rodman, J.; Relling, M.V.; Crom, W.R.; Rivera, G.K.; Crist, W.M.; Pui, C.H. Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia. Semin. Hematol. 1991, 28, 15-21.
30. McLeod, H.L.; Miller, D.R.; Evans, W.E. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient [8]. Lancet 1993, 341, 1151.
31. Relling, M.V.; Yanishevski, Y.; Nemec, I.; Evans, W.E.; Boyett, J.M.; Behm, F.G.; Pui, C.-H. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 1998, 12, 346-352.
32. Relling, M.V.; Rubnitz, I.E.; Rivera, G.K.; Boyett, J.M.; Hancock, M.L.; Felix, C.A.; Kun, L.E.; Walter, A.W.; Evans, W.E.; Pui, C.-H. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 1999, 354, 34-39.
33. Thomsen, J.B.; Schroder, H.; Kristinsson, J.; Madsen, B.; Szumlanski, C.; Weinshilboum, R.; Andersen, J.B.; Schmiegelow, K. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells-Relation to thiopurine metabolism. Cancer 1999, 86, 1080-1086.
34. Pui, C.H.; Relling, M.V. Topoisomerase II inhibitor-related acute myeloid leukaemia. Br. J. Haematol. 2000, 109, 13-23.